Solving Riddles Through Sequencing

Recruiting Observational Study
Leukemia Hematologic Malignancy Rare Diseases Refractory Leukemia Refractory Lymphoma Unknown Primary Tumors
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Munich Leukemia Laboratory · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
During the last decades hematologists have excelled at improving and refining the classification, diagnosis, and thus ultimately the therapeutic decision-making process for their patients. This continuous evolution proceeded in parallel to seminal discoveries in basic science such as FISH, PCR and NGS. So far, the current WHO classification serves as reference to diagnostic decision making and is …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients having been investigated with a suspected hematological disorder and: * Having unclear diagnosis after internal routine diagnosis * Unusual clinical course * Unusual r/r status or non-responder * Multiple parallel hematological conditions * Difficult/rare therapy asso…
Contacts

Torsten Haferlach, MD

+49 (0)89 99017-100

torsten.haferlach@mll.com

CONTACT

Adam Wahida, MD

004917664982845

adam.wahida@tum.de

CONTACT